Cellectar Biosciences and SpectronRx, a radiopharmaceutical contract developer and manufacturer, have signed a commercial supply agreement for the manufacture of Cellectar’s first-in-class cancer therapy, iopofosine I 131, the company announced…
Voximetry has received a Medical Device Single Audit Program (MDSAP) Certificate, bringing the company one step closer to market clearance for clinical use of its Torch Dose Assessment software in…
In 2023, the biohealth industry in Wisconsin contributed $22 billion in economic output and $37.7 billion in total economic impact in the state, combining direct, indirect and induced sources, according…
SHINE Technologies and WARF Therapeutics today announced pre-clinical research results from collaborative efforts with the Advanced Radiotheranostics Lab at the University of Wisconsin. According to a release, the studies showed…
Exact Sciences announced today that the U.S. Food and Drug Administration (FDA) approved its next-generation multitarget stool DNA test called Cologuard Plus. “Cologuard Plus sets a new performance standard in…
Voximetry received a $2 million grant from the U.S. Cancer Institute, part of the National Institutes of Health, to enhance the efficiency and accuracy of conventional nuclear medicine SPECT/CT imaging,…
SHINE Technologies was awarded another Department of Energy’s Small Business Innovation Research Grant to help transform DOE-supported science and technology breakthroughs into viable products and services, creating a bridge between…
SHINE Technologies announced recently that it is entering into a supply agreement with GlyTherix Ltd, an Australian targeted-radiotherapy company specializing in developing antibody radiopharmaceuticals for solid tumors. According to a…
Exact Sciences announced performance data for its blood-based colorectal cancer (CRC) screening test at the European Society of Medical Oncology (ESMO) Congress, the company announced recently. According to a release,…
Invenra announced today that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designations (ODD) to its innovative bispecific antibody, INV724, developed for…
